- Home
- / Precision BioSciences
Precision BioSciences
Stock Price
$8.2
2024-10-29
Market Capitalization
$60.3 M
2024-10-29
Revenue
$34.3 M
FY, 2025
Precision BioSciences Summary
Company Summary
- Overview
- Precision BioSciences is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions.
- Type
- Public
- Status
- Active
- Founded
- 2006
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Cindy Atwell, Vice President, Business Development
Dario Scimeca, General Counsel
Abid Ansari, Chief Financial Officer
Operating MetricsView all
Pre-Clinical Phase Products
4
FY, 2018
Discovery Projects
3
FY, 2018
LocationsView all
1 location detected
Durham, NC
United States
302 E Pettigrew St
Precision BioSciences Financials
Summary Financials
- Revenue (Q1, 2026)
- $10.8M
- Net income (Q1, 2026)
- ($18.4M)
- Cash (Q1, 2026)
- $99.4M
- EBIT (Q1, 2026)
- ($9.1M)
- Enterprise value
- ($33.1M)